Skip to main content
. 2017 Jan 11;2017(1):CD004759. doi: 10.1002/14651858.CD004759.pub2

Ata 2013.

Methods
  • Study design: parallel RCT

  • Study duration: January 2009 to January 2012

  • Study follow‐up: 3 months

Participants
  • Country: Turkey

  • Setting: single centre (Istanbul)

  • Inclusion criteria: adults DD kidney transplant recipients

  • Number: treatment group 1 (11); treatment group 2 (10)

  • Mean age ± SD (years): treatment group 1 (43.6 ± 4); treatment group 2 (37 ± 3.8)

  • Sex (M/F): treatment group 1 (3/8); treatment group 2 (4/6)

  • Exclusion criteria: not reported

Interventions Treatment group 1
  • ATG modified by CD3 count: 1 mg/kg at time of transplant

    • Continued daily for 10 days with dose as follows as per CD3 count

      • > 150/mL: no adjustment

      • 50 to 150/mL: half dose

      • < 50/mL: dose skipped


Treatment group 2
  • ATG standard dose: 1 mg/kg at time of transplant

    • Continued same dose daily for 10 days

    • Dose skipped if lymphocyte count < 300/mL


Maintenance immunosuppression
  • Not specified for either group

Outcomes
  • ATG dose

  • Side effects

  • Graft function at 3 months

  • Acute rejection

  • Infection

  • Cost (CD3+ analysis + ATG)

Notes
  • Brief report only

  • Funding source: not reported

Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Insufficient information to permit judgement
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Not reported but likely not blinded
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Not reported but likely not blinded
Incomplete outcome data (attrition bias) 
 All outcomes Low risk All patient outcome data reported
Selective reporting (reporting bias) Unclear risk Brief report only
Other bias Unclear risk Funding not reported